D927

D927 (DS11252927) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC50 of 0.14 μM. D927 enhances the binding affinity of PI3Kα catalytic subunit p110α to canonical RAS proteins (KRAS4A, KRAS4B) and RRAS, RRAS2, MRAS. D927 activates the PI3Kα-AKT pathway (increasing phosphorylation of AKT, p70S6 kinase) without affecting the RAF-ERK1/2 pathway. D927 improves hyperglycemia in type 1 and type 2 diabetes mice model. D927 can be used for the study of glucose homeostasis disorders and diabetes[1][2].

Product Specifications

CAS Number

[2253733-37-6]

Product Name Alternative

DS11252927

UNSPSC

12352005

Target

Akt; GLUT; PI3K

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/glut4-activator-1.html

Purity

99.46

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

COCCOC1=CC=CC=C1C2=C(SC=C3)C3=C(NC4=CC=C(CC(N)=O)C=C4F)N=N2

Molecular Formula

C23H21FN4O3S

Molecular Weight

452.50

References & Citations

[1]Tsuji T, et al. Discovery of novel pyridazine derivatives as glucose transporter type 4 (GLUT4) translocation activators. Bioorg Med Chem Lett. 2019 Jul 15;29 (14) :1785-1790.|[2]Terayama K, et al. Molecular glues that facilitate RAS binding to PI3Kα promote glucose uptake without insulin. Science. 2025 Jul 24;389 (6758) :402-408.